Helena Canhão Selected Research

Rheumatic Diseases (Rheumatism)

6/2022	Using Patient-Reported Outcome Measures to Evaluate Care for Patients With Inflammatory Chronic Rheumatic Disease.
7/2021	Predicting Biologic Therapy Outcome of Patients With Spondyloarthritis: Joint Models for Longitudinal and Survival Analysis.
7/2021	Obesity and diabetes are associated with disability in women with hand osteoarthritis. Results from the EpiReumaPt nationwide study.
7/2017	Reuma.pt contribution to the knowledge of immune-mediated systemic rheumatic diseases.
4/2017	Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update.
1/2017	Real-life effectiveness of Golimumab in biologic-naïve patients with rheumatoid arthritis - data from the Rheumatic Diseases Portuguese Register (Reuma.pt).
4/2016	Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
6/2015	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers.
1/2015	Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt.
1/2014	The Portuguese Society of Rheumatology position paper on the use of biosimilars.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Helena Canhão Research Topics

Disease

39	Rheumatoid Arthritis 01/2022 - 07/2006
13	Rheumatic Diseases (Rheumatism) 06/2022 - 01/2009
10	Arthritis (Polyarthritis) 01/2019 - 01/2010
9	Tuberculosis (Tuberculoses) 10/2022 - 07/2006
8	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 10/2022 - 01/2007
7	Obesity 01/2024 - 12/2011
7	Infections 01/2022 - 01/2008
7	Inflammation (Inflammations) 01/2018 - 10/2009
7	Necrosis 11/2012 - 07/2006
6	Ankylosing Spondylitis 07/2021 - 07/2006
6	Psoriatic Arthritis 01/2020 - 07/2006
5	Pain (Aches) 01/2023 - 01/2006
5	Latent Tuberculosis 03/2008 - 07/2006
4	Osteoporosis 01/2023 - 09/2004
4	Joint Diseases (Joint Disease) 03/2008 - 07/2006
3	Body Weight (Weight, Body) 07/2022 - 01/2017
3	Chronic Disease (Chronic Diseases) 06/2022 - 10/2019
3	Noncommunicable Diseases 12/2021 - 01/2017
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 04/2013 - 09/2009
2	Staphylococcal Infections 11/2023 - 01/2021
2	COVID-19 01/2022 - 09/2021
2	Osteoarthritis 07/2021 - 12/2012
2	Overweight 01/2021 - 04/2017
2	Disease Progression 10/2019 - 08/2013
2	Axial Spondyloarthritis 07/2017 - 01/2012
2	Autoimmune Diseases (Autoimmune Disease) 05/2016 - 09/2009
2	Bone Resorption 08/2014 - 04/2007
1	Fever (Fevers) 11/2023
1	Abscess 11/2023
1	Osteomyelitis 11/2023
1	Asymptomatic Diseases 01/2022
1	Reinfection 01/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2021
1	Diabetes Mellitus 07/2021
1	Fatigue 01/2021
1	Pathologic Processes 01/2021
1	Atherosclerosis 01/2021
1	Mobility Limitation (Difficulty Walking) 01/2021
1	Atherosclerotic Plaque (Atheroma) 01/2021
1	Vitamin D Deficiency 01/2020
1	Postmenopausal Osteoporosis 04/2019
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2019

Drug/Important Bio-Agent (IBA)

12	Methotrexate (Mexate)FDA LinkGeneric 01/2020 - 01/2007
10	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015 - 07/2006
8	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 01/2015
7	Proteins (Proteins, Gene)FDA Link 07/2022 - 04/2007
6	Antirheumatic Agents (DMARD)IBA 01/2022 - 02/2012
6	Rituximab (Mabthera)FDA Link 02/2016 - 09/2009
4	C-Reactive ProteinIBA 11/2023 - 04/2014
4	CollagenIBA 01/2023 - 01/2010
4	AntibodiesIBA 01/2022 - 04/2013
4	CalciumIBA 01/2021 - 10/2006
4	tocilizumab (atlizumab)FDA Link 01/2017 - 01/2010
4	CytokinesIBA 08/2014 - 01/2010
3	Immunoglobulin G (IgG)IBA 01/2022 - 04/2013
3	golimumab FDA Link 01/2020 - 01/2017
3	EnzymesIBA 12/2019 - 04/2013
3	Hormones (Hormone)IBA 12/2019 - 01/2019
3	Abatacept (Orencia)FDA Link 04/2017 - 01/2010
3	AutoantibodiesIBA 05/2016 - 04/2013
3	LigandsIBA 08/2013 - 01/2011
2	Tuberculin (PPD)IBA 10/2022 - 01/2007
2	Aligeron (AS 2)IBA 12/2021 - 10/2019
2	SteroidsIBA 10/2019 - 01/2009
2	tofacitinibIBA 01/2019 - 01/2018
2	ametantrone (HAQ)IBA 01/2018 - 01/2017
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2017 - 04/2012
2	Prednisolone (Predate)FDA LinkGeneric 01/2017 - 02/2012
2	Antidepressive Agents (Antidepressants)IBA 01/2017 - 04/2012
2	Opioid Analgesics (Opioids)IBA 01/2017 - 04/2012
2	Analgesics (Analgesic Drugs)IBA 01/2017 - 04/2012
2	Peptides (Polypeptides)IBA 05/2016 - 01/2014
2	Rheumatoid FactorIBA 01/2016 - 02/2012
2	Infliximab (Remicade)FDA Link 05/2014 - 10/2009
2	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2012 - 12/2011
1	Fibrillin-1IBA 01/2023
1	OligonucleotidesIBA 01/2023
1	VitronectinIBA 01/2023
1	Interferon-gamma (Interferon, gamma)IBA 10/2022
1	insulin receptor-related receptor (IRR)IBA 01/2022
1	mRNA VaccinesIBA 09/2021
1	HLA Antigens (Human Leukocyte Antigens)IBA 07/2021
1	4-hexyloxyaniline (HOA)IBA 07/2021
1	Prostaglandins AIBA 01/2021
1	N-phthaloylglutamic acidIBA 01/2021
1	alizarinIBA 01/2021
1	GTP-Binding Proteins (G-Protein)IBA 01/2021
1	AdiponectinIBA 01/2021
1	InflammasomesIBA 01/2020
1	hydroxide ionIBA 01/2020
1	Diphosphonates (Bisphosphonates)IBA 04/2019
1	Lysergic Acid Diethylamide (LSD)IBA 07/2018

Therapy/Procedure

25	Therapeutics 01/2021 - 09/2004
12	Biological Therapy 07/2021 - 01/2010
2	Drug Therapy (Chemotherapy) 06/2022 - 04/2012
2	Mediterranean Diet 01/2021 - 01/2018
1	Length of Stay 01/2024
1	Activities of Daily Living (ADL) 01/2023
1	Carotid Endarterectomy 01/2021
1	Hip Replacement Arthroplasty (Total Hip Replacement) 12/2018